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Abstract 
This thesis examines the benefits and costs of screening for colorectal cancer in the 
context of an organised population screening programme. It uses microsimulation 
modelling to derive an optimally cost-effective screening protocol for various 
combinations of the available screening tests. 
First a mathematical model for the natural history of colorectal cancer is derived, 
based on analyses of Australian population and hospital-based cancer registries 
combined with data from published studies. Then a model for population based 
screening is derived based mainly on data from published screening studies, 
including the four major published randomised controlled trials of faecal occult 
blood test (FOBT) screening. These two models are used to simulate the application 
of a screening programme to the Australian population. The simulations are applied 
to a period of 40 years following 1990 (the study’s base year), with both costs and 
benefits discounted back to the base year at an annual rate of 3%. 
The models are applied to simulating a population screening programme based on 
FOBT with a colonoscopy follow up of positive tests. This simulation suggests that 
the optimal application of such a programme would be to offer annual screening to 
people aged 50 to 84 years. Such a programme would lead to a cumulative fall in 
years of life lost to colorectal cancer (YLL) of 28.5% at a cost per year of life saved 
(YLS) of $8,987. These costs and benefits are consistent with those arising from other 
currently funded health interventions. They are also consistent with the cost per 
YLS which Australian governments appear willing to pay for health interventions 
when justified on the basis of cost-effectiveness. The fall in colorectal cancer deaths 
from this screening programme should be first detectable by a national monitoring 
system after around three years of screening. However the full benefits from 
screening would not be realised before around 30 years of screening. 
These simulations are based on the standard guaiac FOBT, but the results suggest 
that significant cost-effective gains could be made by using the newer 
immunochemical FOBT. Further cost-effect gains could be made by offering 
sigmoidoscopy every five years in addition to annual FOBT. 
The models are then applied to simulating population screening programmes using 
colonoscopy and sigmoidoscopy as primary screening tools. Offering colonoscopy 
every ten years to all people aged from 45 to 85 leads to an overall fall in cumulative 
YLL of 37.6%, at a cost of $15,585 per YLS. Offering sigmoidoscopy every three 
years to all people aged 40 to 85 leads to an overall fall in cumulative YLL of 29.1%, 
at a cost of $4,862 per YLS. Both of these cost and benefit results are also consistent 
with the cost per YLS which Australian governments appear willing to pay. The fall 
in deaths with colonoscopy screening would also be detectable after three years of 
screening but the fall with sigmoidoscopy screening would not be detectable until 
after six years of screening. Sigmoidoscopy would need around 35 years of 
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screening to reach its potential gains while colonoscopy screening would not reach 
its full potential during the 40 year screening period. 
Finally the models are applied to targeting people at higher risk of cancer. The 
results show that offering colonoscopy every five years to people at higher risk 
because of a family history of colorectal cancer is a cost-effective addition to the 
annual FOBT screening programme. 
An earlier version of chapter two of this thesis has been published as 
Stevenson CE 1995. Statistical models for cancer screening. Statistical Methods in 
Medical Research; 4: 19–23. 
An expanded version of chapter two, along with parts of chapter one, has been 
published as 
Stevenson CE 1998. Models of screening. In: Encyclopedia of Biostatistics. Armitage P, 
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